Decreased therapeutic effects of noscapine combined with imatinib mesylate on human glioblastoma in vitro and the effect of midkine

Cancer Cell International

Volumn 11, Issue , 2011, Pages

  Erguven, Mine ^a   Bilir, Ayhan ^b   Yazihan, Nuray ^c   Ermis, Ezgi ^c   Sabanci, Akin ^d   Aktas, Esin ^e   Aras, Yavuz ^b   Alpman, Vehbi ^a  

^a ISTANBUL YENI YUZYIL UNIVERSITY   (Turkey)

^b ISTANBUL UNIVERSITY   (Turkey)

^c ANKARA UNIVERSITY   (Turkey)

^d Kyrenia Military Hospital   (Cyprus)

^e ISTANBUL UNIVERSITY   (Turkey)

Author keywords

[No Author keywords available]

Indexed keywords

CASPASE 3; CYCLIC AMP; EPIDERMAL GROWTH FACTOR RECEPTOR; IMATINIB; MIDKINE; MULTIDRUG RESISTANCE PROTEIN 1; NOSCAPINE; PLATELET DERIVED GROWTH FACTOR ALPHA RECEPTOR; PROTEIN; PROTEIN BCL 2; PROTEIN P170; PROTEIN TYROSINE KINASE; UNCLASSIFIED DRUG;

APOPTOSIS; ARTICLE; AUTOPHAGY; CELL CULTURE; CELL CYCLE ARREST; CELL CYCLE G0 PHASE; CELL CYCLE G1 PHASE; CELL DEATH; CELL PROLIFERATION; CELL SURVIVAL; CELL ULTRASTRUCTURE; CELL VACUOLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DRUG EFFECT; GLIOBLASTOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; PROTEIN EXPRESSION; SCANNING ELECTRON MICROSCOPY; STUDENT T TEST; TRANSMISSION ELECTRON MICROSCOPY;

EID: 79958021833     PISSN: None     EISSN: 14752867     Source Type: Journal    
DOI: 10.1186/1475-2867-11-18     Document Type: Article

References (35)

1. Furnari FB, Fenton T, Bachoo RM, Mukasa A, Stommel JM, Stegh A, Hahn WC, Ligon KL, Louis DN, Brennan C, Chin L, DePinho RA, Cavenee WK. Malignant astrocytic glioma: genetics, biology, and paths to treatment. Genes Dev 2007, 21:2683-2710. 10.1101/gad.1596707, 17974913.
2. Zhou Q, Guo P, Gallo JM. Impact of angiogenesis inhibition by sunitinib on tumor distribution of temozolomide. Clin Cancer Rev 2008, 14:1540-1549.
3. Bilir A, Erguven M, Yazihan N, Aktas E, Oktem G, Sabanci A. Enhancement of vinorelbine-induced cytotoxicity and apoptosis by clomipramine and lithium chloride in human neuroblastoma cancer cell line SH-SY5Y. J Neurooncol 2010, 100:385-395. 10.1007/s11060-010-0209-6, 20467784.
4. Aneja R, Miyagi T, Karna P, Ezell T, Shukla D, Vij Gupta M, Yates C, Chinni SR, Zhau H, Chung LW, Joshi HC. A novel microtubule-modulating agent induces mitochondrially driven caspasedependent apoptosis via mitotic checkpoint activation in human prostate cancer cells. Eur J Cancer 2010, 46:1668-1678. 10.1016/j.ejca.2010.02.017, 2883633, 20303260.
5. Zhou J, Gupta K, Yao J, Ye K, Panda D, Giannakakou P, Joshi HC. Paclitaxel-resistant human ovarian cancer cells undergo c-Jun NH2-terminal kinasemediated apoptosis in response to noscapine. J Biol Chem 2002, 277:39777-39785. 10.1074/jbc.M203927200, 12183452.
6. De Vita S, De Matteis S, Laurenti L, Chiusolo P, Sorà F, Piccirillo N, Reddiconto G, Fiorini A, Leone G, Sica S. Imatinib for secondary Ph+ acute lymphoblastic leukemia induces response in concomitant GBM. Ann Oncol 2006, 17:720-721. 10.1093/annonc/mdj056, 16263757.
7. Wen PY, Yung WK, Lamborn KR, et al. Phase I/II study of imatinib mesylate for recurrent malignant gliomas: North American Brain Tumor Consortium Study 99-08. Clin Cancer Res 2006, 12:4899-4907. 10.1158/1078-0432.CCR-06-0773, 16914578.
8. Bayraktar UD, Bayraktar S, Rocha-Lima CM. Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol 2010, 16:2726-2734. 10.3748/wjg.v16.i22.2726, 2883128, 20533592.
9. Ha HT, Lee JS, Urba S, Koenig RJ, Sisson J, Giordano T, Worden FP. A phase II study of imatinib in patients with advanced anaplastic thyroid cancer. Thyroid 2010, 20:975-980. 10.1089/thy.2010.0057, 20718683.
10. Ustach CV, Huang W, Conley-LaComb MK, Lin CY, Che M, Abrams J, Kim HR. A Novel Signaling Axis of Matriptase/PDGF-D/{beta}-PDGFR in Human Prostate Cancer. Cancer Res 2010,
11. Ranza E, Mazzini G, Facoetti A, Nano R. In-vitro effects of the tyrosine kinase inhibitor imatinib on glioblastoma cell proliferation. J Neurooncol 2010, 96:349-57. 10.1007/s11060-009-9975-4, 19629393.
12. Bihorel S, Camenisch G, Lemaire M, Scherrmann JM. Influence of breast cancer resistance protein (Abcg2) and p-glycoprotein (Abcb1a) on the transport of imatinib mesylate (Gleevec) across the mouse blood-brain barrier. J Neurochem 2007, 102:1749-1757. 10.1111/j.1471-4159.2007.04808.x, 17696988.
13. Reardon DA, Dresemann G, Taillibert S, Campone M, van den Bent M, Clement P, Blomquist E, Gordower L, Schultz H, Raizer J, Hau P, Easaw J, Gil M, Tonn J, Gijtenbeek A, Schlegel U, Bergstrom P, Green S, Weir A, Nikolova Z. Multicentre phase II studies evaluating imatinib plus hydroxyurea in patients with progressive glioblastoma. Br J Cancer 2009, 101:1995-2004. 10.1038/sj.bjc.6605411, 2795431, 19904263.
14. Declèves X, Bihorel S, Debray M, Yousif S, Camenisch G, Scherrmann JM. ABC transporters and the accumulation of imatinib and its active metabolite CGP74588 in rat C6 glioma cells. Pharmacol Res 2008, 57:214-222. 10.1016/j.phrs.2008.01.006, 18337118.
15. Muramatsu T. Midkine (MK), the product of a retinoic acid responsive gene, and pleiotrophin constitute a new protein family regulating growth and differentiation. Int J Dev Biol 1993, 37:183-8.
16. Garver RI, Chan CS, Milner PG. Reciprocal expression of pleiotrophin and midkine in normal versus malignant lung tissues. Am J Respir Cell Mol Biol 1993, 9:463-466.
17. Garver RI, Radford DM, Donis-Keller H, Wick MR, Milner PG. Midkine and pleiotrophin expression in normal and malignant breast tissue. Cancer 1994, 74:1584-1590. 10.1002/1097-0142(19940901)74:5<1584::AID-CNCR2820740514 3.0.CO;2-V, 7520350.
18. Konishi N, Nakamura M, Nakaoka S, Hiasa Y, Cho M, Uemura H, Hirao Y, Muramatsu T, Kadomatsu K. Immunohistochemical analysis of midkine expression in human prostate carcinoma. Oncology 1999, 57:253-257. 10.1159/000012039, 10545795.
19. Ye C, Qi M, Fan QW, Ito K, Akiyama S, Kasai Y, Matsuyama M, Muramatsu T, Kadomatsu K. Expression of midkine in the early stage of carcinogenesis in human colorectal cancer. Br J Cancer 1999, 79:179-184. 10.1038/sj.bjc.6690030, 2362182, 10408712.
20. Mishima K, Asai A, Kadomatsu K, Ino Y, Nomura K, Narita Y, Muramatsu T, Kirino T. Increased expression of midkine during the progression of human astrocytomas. Neurosci Lett 1997, 233:29-32. 10.1016/S0304-3940(97)00619-8, 9324232.
21. Landen JW, Hau V, Wang M, Davis T, Ciliax B, Wainer BH, Van Meir EG, Glass JD, Joshi HC, Archer DR. Noscapine crosses the blood-brain barrier and inhibits glioblastoma growth. Clin Cancer Rev 2004, 1:5187-5201.
22. Newcomb EW, Lukyanov Y, Smirnova I, Schnee T, Zagzag D. Noscapine induces apoptosis in human glioma cells by an apoptosisinducing factor-dependent pathway. Anticancer Drug 2008, 19:553-563.
23. Erguven M, Yazihan N, Aktas E, Sabanci A, Li CJ, Oktem G, Bilir A. Carvedilol in glioma treatment alone and with imatinib in vitro. Int J Oncol 2010, 36:857-66.
24. Torres KE, Castillo G, Horwitz SB. Proc Am Assoc Cancer Res 1997, 38:530.
25. Fan W, Miller MC, Cheng RL, Willingham MC. Induction of apoptosis by low concentrations of Taxol is not dependent on a G2/M block. Microsc Microanal 1998, 4:1042-1043.
26. Miller MC, Johnson KR, Willingham MC, Fan W. Apoptotic cell death induced by baccatin III, a precursor of Taxol, occurs without G2/M arrest. Cancer Chemother Pharmacol 1999, 44:444-452. 10.1007/s002800051117, 10550564.
27. Razis E, Selviaridis P, Labropoulos S, Norris JL, Zhu MJ, Song DD, Kalebic T, Torrens M, Kalogera-Fountzila A, Karkavelas G, Karanastasi S, Fletcher JA, Fountzilas G. Phase II study of neoadjuvant imatinib in glioblastoma: evaluation of clinical and molecular effects of the treatment. Clin Cancer Res 2009, 15:6258-6266. 10.1158/1078-0432.CCR-08-1867, 19789313.
28. Ozawa T, Brennan CW, Wang L, Squatrito M, Sasayama T, Nakada M, Huse JT, Pedraza A, Utsuki S, Yasui Y, Tandon A, Fomchenko EI, Oka H, Levine RL, Fujii K, Ladanyi M, Holland EC. PDGFRA gene rearrangements are frequent genetic events in PDGFRAamplified glioblastomas. Genes Dev 2010, 24:2205-2218. 10.1101/gad.1972310, 2947772, 20889717.
29. Spiegl-Kreinecker S, Buchroithner J, Elbling L, Steiner E, Wurm G, Bodenteich A, Fischer J, Micksche M, Berger W. Expression and functional activity of the ABC-transporter proteins P-glycoprotein and multidrug-resistance protein 1 in human brain tumor cells and astrocytes. J Neurooncol 2002, 57:27-36. 10.1023/A:1015735815111, 12125964.
30. Mukai M, Che XF, Furukawa T, Sumizawa T, Aoki S, Ren XQ, Haraguchi M, Sugimoto Y, Kobayashi M, Takamatsu H, Akiyama S. Reversal of the resistance to STI571 in human chronic myelogenous leukemia K562 cells. Cancer Sci 2003, 94:557-563. 10.1111/j.1349-7006.2003.tb01482.x, 12824882.
31. Maiuri MC, Le Toumelin G, Criollo A, Rain JC, Gautier F, Juin P, Tasdemir E, Pierron G, Troulinaki K, Tavernarakis N, Hickman JA, Geneste O, Kroemer G. Functional and physical interaction between Bcl-X(L) and a BH3-like domain in Beclin-1. EMBO J 2007, 26:2527-2539. 10.1038/sj.emboj.7601689, 1868901, 17446862.
32. Zhivotovsky B, Orrenius S. Cell death mechanisms: cross-talk and role in disease. Exp Cell Res 2010, 316:1374-1383. 10.1016/j.yexcr.2010.02.037, 20211164.
33. Bilir A, Erguven M, Oktem G, Ozdemir A, Uslu A, Aktas E, Bonavida B. Potentiation of cytotoxicity by combination of imatinib and chlorimipramine in glioma. Int J Oncol 2008, 32:829-839.
34. Muramatsu T. Midkine, a heparin-binding cytokine with multiple roles in development, repair and diseases. Proc Jpn Acad Ser B Phys Biol Sci 2010, 86:410-425. 10.2183/pjab.86.410, 20431264.
35. Hu R, Yan Y, Li Q, Lin Y, Jin W, Li H, Lu Y, Pang T. Increased drug efflux along with midkine gene high expression in childhood B-lineage acute lymphoblastic leukemia cells. Int J Hematol 2010, 92:105-110. 10.1007/s12185-010-0613-x, 20544404.